Title: Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
Journal: Journal of medicinal chemistry 20141023
Title: The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.
Journal: Antimicrobial agents and chemotherapy 20140601
Title: Treatment of chronic hepatitis C--are interferons really necessary?
Journal: Liver international : official journal of the International Association for the Study of the Liver 20120201
Title: [Improved virologic response in chronic hepatitis C treated with peginterferon, ribavirin and add-on drug].
Journal: Nihon rinsho. Japanese journal of clinical medicine 20110501
Title: Debio-025 is more effective than prednisone in reducing muscular pathology in mdx mice.
Journal: Neuromuscular disorders : NMD 20101101
Title: Pharmacologic targeting or genetic deletion of mitochondrial cyclophilin D protects from NSAID-induced small intestinal ulceration in mice.
Journal: Toxicological sciences : an official journal of the Society of Toxicology 20101101
Title: Structural basis for the non-immunosuppressive character of the cyclosporin A analogue Debio 025.
Journal: Biochemistry 20100608
Title: Debio-025 inhibits HIV-1 by interfering with an early event in the replication cycle.
Journal: Antiviral research 20100201
Title: Alisporivir, a cyclosporin derivative that selectively inhibits cyclophilin, for the treatment of HCV infection.
Journal: Current opinion in investigational drugs (London, England : 2000) 20100201
Title: DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A.
Journal: PloS one 20100101
Title: Modulation of HIV-1 infectivity and cyclophilin A-dependence by Gag sequence and target cell type.
Journal: Retrovirology 20090101
Title: Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy.
Journal: British journal of pharmacology 20081001
Title: Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
Journal: Antimicrobial agents and chemotherapy 20080401
Title: Inhibition of mitochondrial permeability transition improves functional recovery and reduces mortality following acute myocardial infarction in mice.
Journal: American journal of physiology. Heart and circulatory physiology 20070901
Title: Coelmont L, et al. DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One. 2010 Oct 27;5(10):e13687.
Title: Quarato G, et al. The cyclophilin inhibitor alisporivir prevents hepatitis C virus-mediated mitochondrial dysfunction. Hepatology. 2012 May;55(5):1333-43.
Title: de Wilde AH, et al. Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model. Virus Res. 2017 Jan 15;228:7-13.
Title: Esser-Nobis K, et al. The cyclophilin-inhibitor alisporivir stimulates antigen presentation thereby promoting antigen-specific CD8(+) T cell activation. J Hepatol. 2016 Jun;64(6):1305-14.
